
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Cancer Research Campaign Centre for Cancer Therapeutics, E Block, Belmont [S. J. W., L. B., M. V., A. L. J.], and Cancer Research Campaign Centre for Cancer Therapeutics, Haddow Laboratories, Institute of Cancer Research, Sutton [J. T., P. M., G. W. A.], Surrey, SM2 5NG, United Kingdom
Thymidylate synthase (TS) is an important target for cancer chemotherapy. However, several mechanisms of resistance to TS inhibitors have been described. One mechanism that may be relevant to short-term exposure to TS inhibitors occurs as a result of disruption of the autoregulatory loop, which allows TS to control its own translation. This disruption leads to up-regulation of TS protein and is generally thought to decrease efficacy. This study has investigated TS protein up-regulation using a range of TS inhibitors in both tumor and nonmalignant cell lines in vitro and in vivo.
Up-regulation of TS protein showed a time-, dose-, and cell-type-specific response to treatment with ZD9331. This response was observed in W1L2 cells treated for 24 h at equitoxic doses of raltitrexed (6-fold), ZD9331 (10-fold), fluorouracil (5-fold), LY231514 (7-fold), AG337 (7-fold), and BW1843U89 (3-fold). Up-regulation was observed over a range of doses. Elevation of TS protein only persisted up to 12 h after removal of drug. The extent of induction does not depend on basal TS levels. Nontransformed human fibroblasts showed significantly greater up-regulation of TS protein than tumor cells exposed to an equitoxic dose of ZD9331. In vivo experiments using the L5178Y thymidine kinase -/- mouse lymphoma implanted into DBA2 mice also showed greater up-regulation of TS protein in normal intestinal epithelial cells compared with tumor cells.
These results confirm that TS up-regulation is a common feature of TS inhibition in tumor cells and that it may occur to a greater extent in normal tissues, although the clinical implications of these findings remain to be determined.
This article has been cited by other articles:
![]() |
A. Morgenroth, S. Deisenhofer, G. Glatting, F. H-G. Kunkel, C. Dinger, B. Zlatopolskiy, A. T.J. Vogg, T. Kull, and S. N. Reske Preferential Tumor Targeting and Selective Tumor Cell Cytotoxicity of 5-[131/125I]Iodo-4'-Thio-2'-Deoxyuridine Clin. Cancer Res., November 15, 2008; 14(22): 7311 - 7319. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Lee, J.-H. Park, Y. Jung, J.-H. Kim, H.-S. Jong, T.-Y. Kim, and Y.-J. Bang Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells Mol. Cancer Ther., December 1, 2006; 5(12): 3085 - 3095. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Allegra and R. W. Childs Cytotoxins and Cancer Immunotherapy: The Dance of the Macabre? J Natl Cancer Inst, October 5, 2005; 97(19): 1396 - 1397. [Full Text] [PDF] |
||||
![]() |
L. Li, S. H. Berger, and M. D. Wyatt Involvement of base excision repair in response to therapy targeted at thymidylate synthase Mol. Cancer Ther., June 1, 2004; 3(6): 747 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Geller, I. Petak, K. S. Szucs, K. Nagy, D. M. Tillman, and J. A. Houghton Interferon-{gamma}-Induced Sensitization of Colon Carcinomas to ZD9331 Targets Caspases, Downstream of Fas, Independent of Mitochondrial Signaling and the Inhibitor of Apoptosis Survivin Clin. Cancer Res., December 15, 2003; 9(17): 6504 - 6515. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Incles, C. M. Schultes, L. R. Kelland, and S. Neidle Acquired Cellular Resistance to Flavopiridol in a Human Colon Carcinoma Cell Line Involves Up-Regulation of the Telomerase Catalytic Subunit and Telomere Elongation. Sensitivity of Resistant Cells to Combination Treatment with a Telomerase Inhibitor Mol. Pharmacol., November 1, 2003; 64(5): 1101 - 1108. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wu and B. J. Dolnick Detection of Thymidylate Synthase Modulators by a Novel Screening Assay Mol. Pharmacol., January 1, 2003; 63(1): 167 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ciccolini, F. Fina, K. Bezulier, S. Giacometti, M. Roussel, A. Evrard, P. Cuq, S. Romain, P.-M. Martin, and C. Aubert Transmission of Apoptosis in Human Colorectal Tumor Cells Exposed to Capecitabine, Xeloda, Is Mediated via Fas Mol. Cancer Ther., September 1, 2002; 1(11): 923 - 927. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Longley, J. Boyer, W. L. Allen, T. Latif, P. R. Ferguson, P. J. Maxwell, U. McDermott, M. Lynch, D. P. Harkin, and P. G. Johnston The Role of Thymidylate Synthase Induction in Modulating p53-regulated Gene Expression in Response to 5-Fluorouracil and Antifolates Cancer Res., May 1, 2002; 62(9): 2644 - 2649. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. C. Neuteboom, P. L. Karjian, C. R. Boyer, M. Beryt, M. Pegram, G. M. Wahl, and H. M. Shepard Inhibition of Cell Growth by NB1011 Requires High Thymidylate Synthase Levels and Correlates with p53, p21, Bax, and GADD45 Induction Mol. Cancer Ther., April 1, 2002; 1(6): 377 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kawakami, D. Salonga, J. M. Park, K. D. Danenberg, H. Uetake, J. Brabender, K. Omura, G. Watanabe, and P. V. Danenberg Different Lengths of a Polymorphic Repeat Sequence in the Thymidylate Synthase Gene Affect Translational Efficiency but Not Its Gene Expression Clin. Cancer Res., December 1, 2001; 7(12): 4096 - 4101. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |